...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith share issue

noretreat, NBB & BDAZ - I had asked someone to follow up on this to give me clarity. Here is what I found, 10 million shares to be issued between US$ 2.00 and $3.00 for $20 mil to $30 mil to add to their coffers. This is to finance the next leg of the Phase I trial. This would be the breast cancer leg of the trial. 

Given that the time lines on the chart on slide 17 of the PPP changed from 36 weeks to 32 weeks and we would already be there now if the data were brought current, IMO I think something is up. If I am correct in my thinking there may not be a need for an issue by Zenith to happen at this time as another company may be seriously considering taking this forward.

This could easily be wishful thinking on my part but that was some seriously good data presented in the last couple of PPP's.

DYODD

tada

Share
New Message
Please login to post a reply